Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy - 2Figure out How to Augment Your Rooftop Substitution Speculation
- 3Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
- 4When fake data is a good thing – how synthetic data trains AI to solve real problems
- 5Famous Restroom Beautifying Styles For 2024
- Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- Pick Your #1 Sort Of Espresso
- Israel explores creation of int'l force with Greece, Cyprus to deter Turkey
- Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Fascinating Fishing Objections From Around The World
- Ski Resorts Universally: A Colder time of year Wonderland Guide
- 6 U.S. States for Climbing
- Starfront Observatories: A haven for distant stargazers
